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Glucocorticoid-induced sympathoinhibition 
in humans
Objective: To test whether glucocorticoids inhibit sympathetic nerve activity or norepinephrine release in 
humans, as has been suggested by results in laboratory animals.
Methods: This was a double-blind, placebo-controlled, randomized crossover study performed at the 
Clinical Center o f the National Institutes o f Health, Thirteen normal volunteers received 20 mg pred­
nisone or placebo orally each morning for 1 week, followed by a washout period of 1 week and then by 
treatment with the other drug for 1 week. On the last day of cach treatment week, blood samples were 
drawn for measurements of plasma levels o f catecholamines and their metabolites, o f cortisol, and o f  
corticotropin at baseline and during reflexive sympathetic stimulation elicited by lower body negative 
pressure ( — 15 mm H g). A 24-hour urine collection was obtained at the end of each week of treatment 
for measurement o f urinary excretion of catechols. In eight subjects, directly recorded peroneal skeletal 
muscle sympathetic nerve activity was also measured after both treatments.
Remits: Prednisone significantly decreased sympathetic nerve activity by 23% ± 6%, plasma norepineph* 
tine levels by 27% ± 6%, and plasma corticotropin levels by 77%. Blood pressure, heart rate, body 
weight, and urinary excretion of catechols and electrolytes were unaffected. Prednisone did not alter pro­
portionate increments in sympathetic nerve activity or plasma norepinephrine levels during lower body 
negative pressure. Relationships between sympathetic nerve activity and plasma norepinephrine levels 
were unchanged.
Conclusions: Glucocorticoids decrease sympathoneural outflows in humans without affecting acute sym- 
pathoneural responses to decreased cardiac filling and probably without affecting presynaptic modula­
tion of norepinephrine release. (Clin Pharmacol Ther 1995;58:90-8.)
A n n a G olczynska, M D , P h D , Jacques W . M . L en d ers, M D , P h D , and  
D avid  S. G o ld ste in , M D , P h D  Bethesda, MA.
The hypothalarno-pituitary-adrenocortical (HPA), 
sympathoneural, and adrenomedullary systems inter­
act complexly to maintain homeostasis. Exogenously 
administered glucocorticoids are well known to inhibit 
HPA activity. This study focused on effects of exoge­
nously administered glucocorticoids on sympathoneu­
ral function.
Whether glucocorticoids inhibit sympathoneural 
outflows at baseline or during exposure to stimuli that 
increase sympathoneural outflows refiexively has been 
unclear. In rats, hypercortisolemia decreases plasma 
levels of catecholamines and inhibits catecholamine 
synthesis, and endogenous glucocorticoids restrain nor-
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adrenergic responses to immobilization.1,2 
fects are associated with decreased catecholamine syn
thesis and decreased norepinephrine release in 
brain.3 In humans, Stene et al.4 found that oral 
methasone decreased plasma norepinephrine levels at 
baseline and during orthostasis, whereas Rupprecht et 
al,s and Scherrer et al.6 did not. Scherrer et al.6 
reported that dexamethasone did not affect directly re­
corded skeletal muscle sympathetic nerve activity at 
baseline or during the cold pressor test. Sudhir et a l.7
reported that oral hydrocortisone treatment for 1 
at a dose of 200 mg/day increased systolic blood pres­
sure and enhanced forearm vascular responses to in» 
traarterial norepinephrine but did not significantly alter 
estimated rates of norepinephrine spillover into arterial
or forearm venous plasma.
We examined the effects of 1 week of oral treat­
ment with prednisone on plasma levels of 
and on sympathetic nerve activity, during resting con 
ditions and in response to lower body negative pres
sure, in a double-blind, placebo-controlled, random­
ized crossover study of healthy adult volunteers. The 
study was designed to determine whether 1 week of 
glucocorticoid administration to humans would affect 
sympathetic nerve activity, plasma norepinephrine 
levels, or urinary norepinephrine excretion and 
whether the extents of these effects would be propor­
tionately similar. The study also addressed whether 
prednisone treatment alters sympathetic nerve activity 
or norepinephrine responses to lower body negative 
pressure, a laboratory model of orthostasis that de­
creases cardiac filling and reflexively increases sympa­
thoneural outflow.8
METHODS
Subjects. Thirteen healthy volunteers (10 men and 
three women; mean age, 33 years; age range, 21 to 54 
years) participated in the study after each gave written 
informed consent. Each subject had a normal medical 
history, physical examination, screening laboratory 
tests of blood and urine, and electrocardiogram 
(ECG). The participants refrained from smoking and 
from drinking alcohol or caffeinated beverages for 24 
hours before each testing session. The study protocol 
was approved by the Intramural Research Board of the 
National Institute of Neurological Disorders and 
Stroke.
Study design. All subjects were studied twice: after 
20 mg prednisone each morning for 7 days and after 
placebo for 7 days. The sequence of the double-blind 
treatments was randomized. Between the treatments 
there was a washout period of 7 days. A testing ses­
sion occurred on the last day of each treatment. The 
subjects were advised to take the last dose 1 to 2 hours 
before the testing session. The chosen dose of pred­
nisone is known to suppress HPA activity.9
On the morning of each testing session, each sub­
ject delivered a 24-hour collection of spontaneously 
voided urine in a container to which 30 ml of 6 mol/L 
hydrochloric acid had been added. The urine volume 
was recorded and an aliquot frozen for assays of levels 
of catechols, creatinine, sodium, and potassium.
Setup. The experiments were conducted in a quiet 
room with constant temperature (about 24° C) and 
with the subjects in the supine position. Blood pres­
sure was measured with an automated cuff device 
(Critikon, Inc., Tampa, Fla.). Heart rate was recorded 
continuously by ECG. An intravenous catheter was in­
serted for sampling blood.
Microneurography. In eight subjects, multifiber re­
cordings of sympathetic nerve activity were obtained 
successfully after both drug treatments from a muscle
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fascicle of the peroneal nerve at the head of the fibula. 
The right and left peroneal nerves were used alterna­
tively for the two study sessions. The course of the 
nerve was mapped with transcutaneous electrical 
stimulation (40 to 60 V, 0.2 msec, 1 Hz) with use of a 
pencil-shaped electrode. A sterile tungsten-wire mi- 
croelectrode was inserted in the region of the nerve. A 
similar reference electrode was inserted subcutane- 
ously 1 to 3 cm from the recording electrode. Weak 
electrical stimuli (2 to 4 V, 0.2 msec, 1 Hz) were de­
livered to the recording electrode with a stimulator 
connected to an isolation unit. The elicitation of invol­
untary twitches in the lower leg indicated that the 
electrode tip was located within or close to the muscle 
nerve fascicle. The electrode was then moved until 
there was acceptable recording from sympathetic 
nerve fibers. Recording of sympathetic nerve activity 
was accepted if (1) tapping or stretching the muscles 
or tendons supplied by the impaled nerve produced af­
ferent mechanoreceptor discharges, while rubbing the 
skin in the sensory field of the nerve evoked no affer­
ent response, and (2) spontaneous, pulse-synchronous 
bursts of muscle sympathetic nerve activity were ob­
served, with the frequency and amplitude of the bursts 
increasing during held expiration but not during 
arousal stimuli. Electrodes remained in place through­
out the study. The electrodes were connected to a 
preamplifier (gain, 1000) and an amplifier (gain, 70). 
The nerve signals were played through a loudspeaker, 
displayed on a monitor, and recorded with the 
MacLab/8 data recording system (ADInstruments, 
Castle Hill, Australia) and a Macintosh computer. The 
number and the amplitude of sympathetic bursts were 
measured during 5-minute periods and expressed in 
bursts per minute and microvolts per minute. The 
measurements were performed with use of Chart and 
Peaks software from ADInstruments.
Lower body negative pressure. The legs and lower 
abdomen of the subject were enclosed in a specially 
designed lower body negative pressure chamber, with 
a hinged door permitting access to the leg for nerve 
recordings (Medical Instruments, University of Iowa, 
Iowa City, Iowa). The chamber was sealed around the 
upper abdomen of the subject with plastic sheeting 
and was attached to a vacuum motor.
JExperimental protocol. After the subject had been 
at supine rest for at least 15 minutes, blood pressure 
was recorded each minute and heart rate and sympa­
thetic nerve activity were recorded continuously for 5 
minutes. Baseline blood samples (about 10 ml) were 
drawn. Lower body negative pressure was then ap­
plied at —15 mm Hg for 15 minutes. Blood pressure
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Table I. Effects of prednisone treatment (20 mg orally each morning) on blood pressure, heart rate, skeletal 
muscle sympathetic nerve activity, and plasma levels of catechols, at baseline and in response to lower body
negative pressure (—15 mm Hg) in healthy volunteers
Placebo Prednisone
Baseline LBNP Baseline
Body weight (kg) 
Systolic BP (mm Hg) 
Diastolic BP (mm Hg) 
MAP (mm Hg)
Heart rate (beats/min)
(bursts/min)
(ijiV/min)
Norepinephrine (nmol/L) 
Epinephrine (nmol/L) 
Dihydroxyphenylglycol (nmol/L) 
Dihydroxyphenylalanine (nmol/L)
(nmol/L)
LBNP, Lower body negative pressure; BP, blood pressure; MAP, mean arterial blood 
*p <  0.05; **p <  0.01; ***/? <0.001, lower body negative pressure versus baseline, 
t p <  0.05; t t p <  0,01; t t tp  <  0.001, prednisone versus placebo*
LBNP
75.7 ±  4.0 76.0 ± 4 .1
123 ±  5** 119 ± 5 116 ±  3 117
69 ±  3 10 ± 2 67 ±  1 67
87 ±  3 86 ±  3 84 ±  2 84
63 ± 3 64 ±  3 61 ±  3** 64
42 ± 3* 48 ±  4 33 ±  4t1i** 37
98.6 ±  12.8* 157.1 ± 25.7 52.9 ±  5 .7 tt 74.3
1.46 ±  0.14** 1.88 ±  0.22 1.02 ±  O.lOtt*** 1.32
0.15 ±  0.03 0.14 ±  0.03 0.11 ±  0.02 0.11
6.00 ±  0.36 6.41 ±  0.47 4.75 ±  0.21tt** 5.26
8.87 ±  0.66 9.47 ±  0.90 7.40 ±  0.46tt* 7.83
9.95 ± 1.69 9.06 ±  1.14 9.14 ±  1.41 9.31
± 4 
± i 
± 2 
± 3
5tt
14.31*
0.12tt
0.02
0.32tt
0.53
1.29
was recorded each minute, and heart rate and sympa­
thetic nerve activity were recorded continuously for 
the last 5 minutes of lower body negative pressure. In 
the last minute of lower body negative pressure, an­
other blood sample was drawn.
Assays. Blood samples were collected into chilled 
heparinized glass tubes and centrifuged at 4° C and 
3500# for 15 minutes before storage of the plasma at 
-75° C until assayed. Plasma and urine levels of cat­
echols were assayed by liquid chromatography with 
electrochemical detection after adsorption on alumi­
num oxide.10,11 The limits of detection were about
0.04 nmol/L for norepinephrine and about 0.06 
nmol/L for epinephrine. Intraassay and interassay co­
efficients of variation for catechol assays in this labo­
ratory have been published previously.10 Urine con­
centrations of creatinine, sodium, and potassium were 
assayed according to standard clinical laboratory 
methods. Serum cortisol levels were measured by ra­
dioimmunoassay (Quanticoat, Kallestad Diagnostics, 
Chaska, Minn.). The antibody crossreacts minimally 
with prednisone at 0.39% and has a sensitivity of 0.5 
|xg/dl. The intraassay coefficient of variation (CV) 
was less than 10%. Plasma corticotropin levels were 
measured by a highly specific two-site radioimmuno­
assay (Nichols Institute Diagnostics, San Juan Capis­
trano, Calif.) with a sensitivity of 1 pg/ml and intra­
assay coefficient of variation of less than 5%.
Data analysis. Results are presented as mean values 
±SE. Responses were expressed both as absolute and
\
as percentage changes from the resting values. Paired 
t  tests were used to compare the effects of prednisone 
on basal values and to assess the effects of lower body 
negative pressure during each treatment. Two-way 
ANOVA was used to test for interactions between 
prednisone treatment and responses to lower body 
negative pressure. The average coefficient of correla­
tion between sympathetic nerve activity and plasma 
norepinephrine levels was calculated using the Fisher 
z transformation. A p  value less than 0.05 defined sta­
tistical significance.
RESULTS
Effects of prednisone. Predr 
a dose of 20 mg each morning 
feet systolic, diastolic, or mean blood pressures, heart 
rate, or body weight (Table I). Plasma cortisol levels 
averaged 9.9 ±  1.3 |xg/dl during placebo and 8.6 ±
1.4 |ig/dl during prednisone (difference not signifi­
cant). Plasma corticotropin levels decreased by a 
mean of 77%, from 25.2 ±  5.6 to 5.1 ±  1.3 pg/ml 
(p <  0.01).
For all eight subjects in whom microneurographic 
recordings were obtained successfully after both treat­
ments, prednisone suppressed sympathetic nerve ac­
tivity (Table I). The proportionate decrease averaged 
23% nerve
per
nerve
volts per minute. Individual values for sympathetic
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Fig. 1. Correlations between indexes of sympathetic nervous system activity after placebo and 
prednisone treatment, at baseline (BL) and during lower body negative pressure (LBNP). A, Mus­
cle sympathetic nerve activity. B, Antecubital venous plasma levels of norepinephrine.
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Table II. Effects of prednisone (20 mg orally 
each morning) on 24-hour urinary excretion of 
electrolytes, creatinine, and catechols in normal 
volunteers
Placebo Prednisone
Creatinine (gm) 1.70 0.24 1.62 ± 0.19
Sodium (mmol) 128 25 132 W M « * 26
Potassium (mmol) 62 üb 9 56 13
Norepinephrine (nmol) 1.61 ± 0.31 1.61 Í 0.27
Epinephrine (nmol) 0.21 ± 0.05 0.14 0.02
Dopamine (nmol) 10.43 ± 1.30 10.39 ± 0.98
Dihydroxyphenyl- 2.74 -f- 0.39 2.87 0.38
glycol (nmol)
Dihydroxyphenylala­ 0.74 H- 0.13 0.76 0.15
nine (nmol)
Dihydroxyphenyl­ 49.7 ± 8.9 55.5 9.6
acetic acid (nmol)
Volume (ml) 1173 ± 109 1280 253
« M M * « ! m m
There were no statistically significant differences in values for the above 
indexes between the placebo and prednisone treatments.
nerve activity in the two study sessions were closely 
related, and the slopes of the regression lines were 
close to 1 (Fig. 1, A).
Plasma norepinephrine levels decreased signifi­
cantly by 27% ± 6% during prednisone treatment. 
Plasma norepinephrine levels were positively corre­
lated between the two treatments (Fig. 1, B)\ the 
slopes of the regression lines for plasma norepineph­
rine levels were significantly smaller than 1. Pred­
nisone also significantly decreased plasma levels of di­
hydroxy phenylgly col (DHPG) by 18% ±  5% and 
dihydroxyphenylalanine (DOPA) by 15% ±  4%. 
Prednisone did not significantly alter plasma levels of 
epinephrine or dihydroxyphenylacetic acid (DOPAC, 
Table I).
Prednisone treatment did not affect 24-hour urinary 
excretion rates of norepinephrine or of other catechols 
(Table II). The 24-hour urinary excretion rates of so­
dium, potassium, and creatinine did not differ be­
tween the two treatment phases.
Effects of lower body negative pressure. After pla­
cebo treatment, lower body negative pressure pro­
duced slight but consistent decreases (p <  0.01) in 
systolic blood pressure, without affecting diastolic or 
mean blood pressure or heart rate (Table I).
Lower body negative pressure increased sympa­
thetic nerve activity and plasma norepinephrine levels 
in all subjects. Sympathetic nerve activity increased 
by 20% ±  6% when expressed as bursts per minute 
and by 58% ± 19% when expressed as microvolts per 
minute (Fig. 2). Plasma norepinephrine levels in-
creased by 27% dihydroxyphenylgly
col levels increased slightly and nonsignificantly by
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Fig. 3. Relationships between muscle sympathetic nerve activity and plasma levels of norepineph­
rine after placebo and prednisone treatment. BL, Baseline; LBNP, lower body negative pressure 
( -1 5  mmHg). Top panel, Individual values. Bottom, Mean values ±  SEM.
7% ±  3% (Table I); plasma epinephrine, dihydroxy- 
phenylalanine, and dihydroxyphenylacetic acid levels
were unchanged.
Effects of prednisone on responses to lower body 
negative pressure. After prednisone treatment, lower 
body negative pressure did not affect systolic, dia­
stolic or mean blood pressures and slightly but consis­
tently increased heart rate ip <  0.01; Table I). 
ANOVA indicated a significant effect of prednisone 
treatment on responses of systolic blood pressure to 
lower body negative pressure.
Neither absolute nor proportionate responses of 
sympathetic nerve activity during lower body negative 
pressure differed between placebo (8 ±  2 bursts/min; 
20% ±  6%) and prednisone (5 ±  1 bursts/min; 
21% ± 7%) treatments (Table I; Fig. 2). The mean 
absolute and proportionate increments in plasma nor­
epinephrine levels during lower body negative pres­
sure were not significantly changed by prednisone 
treatment (0.30 ±  0.06 versus 0.42 ±  0.11 nmol/L 
and 34% ±  8% versus 27% ±  6%; Table I; Fig. 2). 
After prednisone, plasma dihydroxyphenylglycol lev­
els during lower body negative pressure increased by 
10% ± 3 % (p <  0.01; Table I), an amount that did 
not differ from that after placebo. Responses of 
plasma epinephrine, dihydroxyphenylalanine, and di­
hydroxyphenylacetic acid levels during lower body 
negative pressure also did not differ between the two 
treatments. ANOVA revealed no significant interac­
tion effects between prednisone treatment and re­
sponses of any of the dependent neuronal or neuro­
chemical measures during lower body negative 
pressure.
Antecubital plasma norepinephrine levels correlated 
positively with sympathetic nerve activity levels (aver­
age correlation coefficient, 0.67; p <  0.01; Fig. 3). 
Prednisone treatment did not change the relationship 
between sympathetic nerve activity and plasma nor­
epinephrine levels at baseline or during lower body 
negative pressure (Fig. 3).
DISCUSSION
The main findings in this double-blind, placebo- 
controlled, randomized crossover study were that oral 
prednisone administration at a dose of 20 mg/day de­
creased directly recorded skeletal muscle sympathetic 
nerve traffic and concurrently decreased antecubital 
venous plasma levels of the sympathetic neurotrans­
mitter norepinephrine and of its intraneuronal metabo­
lite dihydroxyphenylglycol.
The results extend to humans previous observations 
from studies of laboratory animals in which 1 week of
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cortisol administration by means of a subcutaneous 
minipump reservoir reduced baseline norepinephrine 
concentrations in arterial plasma by about 50% in con­
scious rats.2,12 The results of this study about pred­
nisone effects agree with those about dexamethasone 
effects in the study of Stene et al.4 but disagree with 
those about dexamethasone effects in the studies of 
Rupprecht et al.5 and Scherrer et al.6 None of these 
studies involved a double-blind, placebo-controlled, 
crossover design.
Mineralocorticoids can inhibit sympathoneural out­
flows, as indicated by decreased plasma norepi­
nephrine levels13 and decreased sympathetic nerve 
activity,14 in normal volunteers treated with 9a- 
fludrocortisone acetate and in patients with primary 
aldosteronism.15 Mineralocorticoid-induced sympa- 
thoinhibition may result from activation of low- and 
high-pressure baroreceptors caused by extracellular 
volume expansion and arterial hypertension. Because 
prednisone did not affect body weight, electrolyte ex­
cretion, pulse rate, or blood pressure in this study, 
baroreceptor activation seems to be an unlikely expla­
nation for prednisone-induced sympathoinhibition.
The reductions in directly recorded sympathoneural 
activity raise the possibility that glucocorticoids in­
hibit sympathetic outflows by actions in the central 
nervous system. Endogenous and synthetic glucocorti­
coids cross the blood-brain barrier relatively easily, 
and the cerebral cortex and most noradrenergic and 
adrenergic cells in the rat brain possess nuclear glu­
cocorticoid receptors.16 Removal of endogenous corti­
costeroids by bilateral adrenalectomy increases nor­
epinephrine turnover in the whole brain and in specific 
areas such as the hypothalamus.3,17 Conversely, hy~ 
percortisolemic rats have neurochemical changes that 
indicate decreased release of norepinephrine and de­
creased catecholamine biosynthesis in the paraven­
tricular nucleus of the hypothalamus.12
The possibility of ganglionic blockade by glucocor-
as an explanation for prednisone-induced sympatho­
inhibition. Whether or not sympathetic ganglia pos­
sess cytoplasmic glucocorticoid receptors has been un­
clear.18,19 Cortisol and corticosterone hyperpolarize 
celiac ganglion cells, with a short latency that sug­
gests that membrane-bound glucocorticoid receptors 
may decrease ganglion cell activity by a nongenomic 
mechanism.20 Sympathetic ganglia also possess func­
tional receptors for corticotropin-releasing hormone,21 
and exogenously administered glucocorticoids, by de­
creasing release of corticotropin-releasing hormone, 
theoretically could affect ganglionic transmission.
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Prednisone treatment did not affect increments in 
sympathetic nerve activity or plasma norepinephrine 
levels during lower body negative pressure, suggest­
ing that although prednisone inhibited sympathoneural 
outflows at baseline, it did not attenuate reflexive 
sympathoneural responses to decreased cardiac filling. 
Analogously, hypercortisolemia does not affect 
plasma norepinephrine responses to nitroprusside- 
induced hypotension in rats.2,22 Inhibitory effects of 
other glucocorticoids on sympathoneural responses 
seem to vary with the type of stressor.6,23
Prednisone treatment also did not alter relationships 
between sympathetic nerve activity and plasma levels 
of norepinephrine at baseline or during lower body 
negative pressure. These findings suggest that, in hu­
mans, glucocorticoids do not affect presynaptic modu­
lation of norepinephrine release from sympathetic 
nerves. Analogously, in pithed rats, glucocorticoid 
treatment does not alter plasma norepinephrine re­
sponses to electrical stimulation of the entire sympa­
thetic outflow.24
The 24-hour urinary excretion of catecholamines re­
mained unchanged after prednisone treatment, despite 
decreased levels of sympathetic nerve activity and of 
antecubital plasma norepinephrine. The sympatho- 
inhibitory effect of prednisone may be too brief and 
too small to affect daily urinary norepinephrine excre­
tion . In addition, local release of norepinephrine in the 
kidneys contributes importantly to urinary norepineph­
rine excretion,25 Because sympathetic neural outflows 
to various organs are differentiated,26 it is possible 
that prednisone did not suppress sympathoneural traf­
fic to the kidneys and therefore did not decrease uri­
nary norepinephrine excretion.
Lower body negative pressure produced small but 
significant decreases in systolic blood pressure during 
the placebo phase, whereas lower body negative pres­
sure increased heart rate without affecting systolic 
blood pressure during the prednisone phase. Because 
sympathoneural responses to lower body 
pressure did not differ between the placebo and pred­
nisone treatment phases, the results suggest that al­
tered postsynaptic responsiveness could have pro­
duced these small but statistically significant 
hemodynamic differences. Patients with Cushing’s 
disease27 and subjects treated for 1 week with oral hy­
drocortisone 7 have been reported to have enhanced 
pressor and vasoconstrictor responses to exogenous 
norepinephrine. Patients with Cushing’s disease also 
have increased cardiac sensitivity to isoproterenol.28 
Analogously, arterial walls and cardiac tissue from 
rats treated with dexamethasone have increased
postsynaptic sensitivity to catecholamines. 29 This
could be explained by an ability of dexamethasone to 
increase gene expression for a r-adrenergic receptors 
in smooth muscle cells.30
With use of a highly sensitive radioimmunoassay 
for corticotropin, and consistent timing of blood sam­
pling, this study revealed decreased corticotropin 
plasma levels during prednisone treatment compar­
ing with placebo treatment in every subject tested, 
verifying that the dose of 20 mg/day prednisone was 
adequate to attenuate HPA activity, as reported in 
other studies.9 Nevertheless, simultaneously obtained
cortisol levels remained unchanged. Other 
clinical studies have reported analogous dissociation 
between cortisol and corticotropin changes in normal 
subjects.31,32 Thus, factors other than corticotropin 
appear to contribute to regulation of adrenocortical se­
cretion .
In summary, the results of this study indicate that 
prednisone decreases sympathoneural outflows in 
healthy humans without affecting reflexive sympatho­
neural responses during lower body negative pressure, 
a laboratory model of orthostasis, and without affect­
ing modulation of norepinephrine release from sympa­
thetic nerves.
We thank Dr. George Chrousos and Dr. Costantine 
Tsigos for arranging and conducting the cortisol and cortico­
tropin assays.
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